Centre Hospitalier Régional et Universitaire de Lille, Lille, France; Faculté de Médecine de Lille, Lille, France.
Am J Cardiol. 2012 Jul 15;110(2):277-83. doi: 10.1016/j.amjcard.2012.02.069. Epub 2012 Apr 5.
Left ventricular (LV) remodeling after myocardial infarction (MI) indicates a high risk of heart failure and death, but LV remodeling remains difficult to predict. Biomarkers may help to refine risk stratification for a more personalized medical approach. They may also shed light on the pathophysiologic processes involved. We performed a systematic review of the published evidence about the association of circulating biomarkers with LV remodeling after MI. We selected 59 publications. Overall, these studies examined 112 relations between 52 different biomarkers and LV remodeling. The biomarkers most consistently associated with LV remodeling were involved in extracellular matrix turnover or neurohormonal activation: matrix metalloproteinase-9, collagen peptides, and B-type natriuretic peptide. This review underscores the vitality of the research on LV remodeling but concludes that the ideal biomarker has not yet been identified. To reach this goal, future studies will have to be larger, have standardized imaging end points, and include replication populations to define optimal cutoffs for LV remodeling prediction. Cardiovascular magnetic resonance appears to be the best technique for LV remodeling assessment but its current availability may be a concern for recruitment for multicenter studies. Recent technologic advances will probably yield new candidate biomarkers of LV remodeling. Tests are necessary to determine whether a multimarker approach would significantly improve risk prediction.
左心室(LV)重构是心肌梗死后心力衰竭和死亡的高危因素,但 LV 重构仍然难以预测。生物标志物有助于完善风险分层,实现更个体化的医疗方案。它们也有助于阐明相关的病理生理过程。我们对已发表的关于循环生物标志物与心肌梗死后 LV 重构之间关系的证据进行了系统评价。我们共选取了 59 篇文献。这些研究共探讨了 52 种不同生物标志物与 LV 重构之间的 112 种关系。与 LV 重构关系最密切的生物标志物涉及细胞外基质转换或神经激素激活:基质金属蛋白酶-9、胶原肽和 B 型利钠肽。这篇综述强调了 LV 重构研究的活力,但结论是尚未确定理想的生物标志物。为实现这一目标,未来的研究必须更大规模、有标准化的影像学终点,并纳入复制人群,以确定用于 LV 重构预测的最佳截断值。心血管磁共振似乎是 LV 重构评估的最佳技术,但目前其普及度可能会影响多中心研究的招募。最近的技术进步可能会产生新的 LV 重构候选生物标志物。需要进行检测以确定多标志物方法是否能显著提高风险预测的准确性。